CURRENT USE AND OUTCOMES OF CELLULAR THERAPY: BRAZILIAN SUMMARY SLIDES -2025
DOI:
https://doi.org/10.46765/2675-374X.2025v6n1p271Abstract
Chimeric antigen receptor T-cells (CAR T cells) are genetically modified cellular immunotherapies approved as a standard of care treatment for patients with lymphoma and leukemia worldwide. Here, we report the initial activity in Brazilian centers through the collaboration between the Brazilian Cellular Therapy and Bone Marrow Transplant Society (SBTMO) and the Center for International Blood and Marrow Transplant Research (CIBMTR). A total of 104 patients who received commercial and academic CAR-T cells in Brazil between January 2020 and April 2025 were included. The median age was 56 years (range 4-83). Indications were Non-Hodgkin Lymphoma (NHL; 75 cases; 72%), Acute Lymphoblastic Leukemia (ALL; 23 cases; 22%), Multiple Myeloma (MM; 4 cases; 4%) and Chronic lymphoblastic leukemia (CLL; 2 cases; 2%). Anti-CD19 commercial CAR-T were 82% of the total, 68 for NHL and 17 for ALL). Most deaths were due to disease progression or relapse (n=19), followed by infections (n=8). The overall survival after a median follow-up of 200 days was 73% (95% CI: 62-86; N=63) for NHL and 79% (95% CI: 63-99; N=19) for ALL. This report demonstrates the successful initial implementation of CAR-T cells in Brazil among centers that report to the SBTMO/CIBMTR. This infrastructure will assist in further capturing the activity, assessing the outcomes, and complying with regulatory requirements.
Downloads
Published
How to Cite
Issue
Section
License
Copyright (c) 2025 JOURNAL OF BONE MARROW TRANSPLANTATION AND CELLULAR THERAPY
This work is licensed under a Creative Commons Attribution 4.0 International License.
License and Copyright Policy
The Journal of Bone Marrow Transplantation and Cellular Therapy (JBMTCT) adopts an open access policy, ensuring that all published articles are freely available to the public without restrictions.
-
License
- All articles published in JBMTCT are licensed under the Creative Commons Attribution 4.0 International License (CC BY 4.0).
- This license permits anyone to:
- Share: Copy and redistribute the material in any medium or format.
- Adapt: Remix, transform, and build upon the material for any purpose, even commercially.
- The only requirement is that appropriate credit is given to the original authors and source, a link to the license is provided, and any changes made are indicated.
More information about the license can be found here: Creative Commons Attribution 4.0 International License.
-
Authors’ Rights
- Authors retain the copyright to their work.
- Authors grant JBMTCT the right to publish the work and make it openly accessible online.
- Authors are free to:
- Distribute the published version of their article (e.g., post it on personal websites or institutional repositories).
- Use the article in future works, presentations, or derivative publications, as long as the original publication in JBMTCT is properly acknowledged.
-
No Embargo
- There is no embargo period; articles are made freely available immediately upon publication.
-
Ethical Use
- Users of JBMTCT articles must ensure proper citation of the authors and the journal.
- Articles must not be used in ways that violate ethical or legal standards.
-
Disclaimer
- While JBMTCT aims to ensure the accuracy and reliability of published content, the journal and its editors are not responsible for the consequences of its use.
For any questions regarding our licensing terms, please contact us at: journalbmtct@sbtmo.org.br
JBMTCT is committed to the principles of open access to advance knowledge and scientific collaboration.
